GET DAILY SIGNALSMoleculin Biotech (MBRX) Shares Drop -29% After Reverse Split
Key Takeaways
- MBRX shares have declined roughly 29% over the last 30 days, from about $11.38 in late September to about $8.10 on a split-adjusted basis.
- The main catalyst was a 1-for-20 reverse stock split, announced October 16 and effective October 20, which reduced the share count from approximately 20.9 million to about 1.05 million and pressured investor sentiment.
- Over the last three months, the stock is down roughly 82%, extending a slide that began with a deeply discounted equity offering and mixed clinical data in late July.
- Moleculin Biotech is a pre-revenue, Phase 3 clinical-stage company whose lead candidate, Annamycin, is being studied in relapsed or refractory acute myeloid leukemia.
- Funding and dilution remain central risks; the company priced a $9.3 million public offering at $0.75 per share in late July and still generates no product revenue.
- For additional data on the ticker's Price Targets, Earnings, and Forecast, explore Tickeron's dedicated pages.
- For automated trading ideas, readers can also explore Tickeron's Trending AI Robots.
Company Background and Pipeline Focus
Moleculin Biotech, Inc. (MBRX) is a Phase 3 clinical-stage biopharmaceutical company based in Houston. Its lead program centers on Annamycin, a next-generation anthracycline intended to sidestep multidrug resistance and cardiotoxicity issues seen with older versions. The candidate is advancing in the pivotal MIRACLE trial for relapsed or refractory acute myeloid leukemia and is also under study for soft tissue sarcoma lung metastases. Earlier-stage efforts include the WP1066 portfolio for various cancers and the WP1122 portfolio targeting select viruses and cancers. As a pre-revenue developer, the company's value hinges on clinical progress and financing capacity. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Price Action: 30-Day and Quarterly Moves
On a split-adjusted basis, MBRX closed near $11.38 in late September and traded near $8.10 in late October, marking a decline of roughly 29% over the past 30 days. The October 16 announcement of a 1-for-20 reverse stock split, effective October 20, reduced outstanding shares from approximately 20.9 million to about 1.05 million. While reverse splits can mechanically support listing compliance, the broader trend has been downward. Over the last three months, shares have fallen roughly 82%, from about $43.80 in late July to current levels, reflecting ongoing selling pressure.
Factors Behind the 30-Day Decline
The standout event in the past month was the reverse stock split. The October 16 announcement aimed to address a sub-$1 share price and Nasdaq requirements, but it triggered immediate selling as investors weighed the capital-structure change against ongoing cash needs. The move extended a decline that began after a discounted equity raise and mixed clinical data in late July. On October 20, the company issued a CEO Corner update noting continued MIRACLE trial progress, yet share-structure concerns dominated sentiment. From what I see, this type of event often amplifies short-term volatility in small-cap names.
Quarterly Performance Drivers
The larger quarterly drop traces to July 31, when Moleculin released updated blinded preliminary data from Part A of the Phase 2/3 MIRACLE trial and simultaneously priced a $9.3 million public offering at $0.75 per share with warrants. The discounted terms and lower-than-expected blinded remission figures contributed to a single-session drop exceeding 60%. The stock stabilized somewhat through August and early September but resumed its slide amid focus on limited cash runway, lack of product revenue, and the upcoming reverse split. I’m watching this closely because dilution risk remains a recurring theme for pre-revenue biotechs.
Key Items on the Horizon
Attention is likely to stay on MIRACLE trial milestones. The company expects to treat its 90th patient in September 2026, with full data unblinding targeted between December 2026 and February 2027. Additional funding needs, any post-split trading dynamics, and updates on Annamycin or the earlier-stage programs could influence the stock. Given the pre-revenue status and finite cash, the ability to complete the trial stands out as a central consideration, along with broader biotech market conditions.
Exploring Tickeron’s Trending AI Robots
I frequently review Tickeron’s Trending AI Robots page when assessing automated strategies across sectors like biotech. It highlights top-performing bots from hundreds available, covering different timeframes and approaches so traders can compare results in varying market environments. This gives a useful data-driven view of momentum signals without replacing individual due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MBRX's RSI Indicator climbs out of oversold territory
The RSI Oscillator for MBRX moved out of oversold territory on October 23, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 46 similar instances when the indicator left oversold territory. In 41 of the 46 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on MBRX as a result. In 65 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for MBRX just turned positive on October 23, 2026. Looking at past instances where MBRX's MACD turned positive, the stock continued to rise in 31 of 40 cases over the following month. The odds of a continued upward trend are 77%.
Following a +42.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBRX advanced for three days, in 176 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
MBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MBRX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.386) is normal, around the industry mean (3.151). P/E Ratio (0.599) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. MBRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry Biotechnology
Advertisement